ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2022
A metabolite panel that differentiates Alzheimer's disease from other dementia types.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Polyol pathway dysregulation in CSF links glucose metabolism to tau pathology independently of amyloid and genetic predisposition.medRxiv : the preprint server for health sciences · 2026Article
- Metabolomic levels mediate the link between socioeconomic factors and changes in declarative memory in women with and without HIV.Brain, behavior, & immunity - health · 2026Article
- Identification of plasma biomarkers in lipid metabolism for accurate prediction of Alzheimer's disease.Translational psychiatry · 2026Article
- Plasma Metabolic Characteristics and Potential Biomarker Combinations in Schizophrenia Patients With Tardive Dyskinesia.Schizophrenia bulletin · 2026Article
- Filtration-enriched metabolites and their association with salivary microbiota: a combined two-cohort analysis.Journal of oral microbiology · 2026Article
- Plasma Lyso-PE 22:6 and Lyso-PE 20:4 are associated with development of mild to moderate depression revealed by metabolomics: a pilot study.BMC psychiatry · 2025Article
- Insomnia, Cognitive Impairment, or a Combination of Both, Alter Lipid Metabolism Due to Changes in Acylcarnitine Concentration in Older Persons.Metabolites · 2025Article
- Application of IVDr NMR spectroscopy to stratify Parkinson's disease with absolute quantitation of blood serum metabolites and lipoproteins.Scientific reports · 2025Article
- Innovations in Alzheimer's disease diagnostic technologies: clinical prospects of novel biomarkers, multimodal integration, and non-invasive detection.Frontiers in neurology · 2025Review
- Article
- Biofluid biomarkers for Alzheimer's disease: past, present, and future.Medical review (2021) · 2024Review
- Discovery of novel metabolic biomarkers in blood serum for diagnosis of Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2024Article
- Investigating metabolic dysregulation in serum of triple transgenic Alzheimer's disease male mice: implications for pathogenesis and potential biomarkers.Amino acids · 2024Article
- Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer's Disease.International journal of molecular sciences · 2024Review
- Dysregulation ofCurrent Alzheimer research · 2024Article
- Lipid metabolism and oxidative stress in patients with Alzheimer's disease and amnestic mild cognitive impairment.Brain pathology (Zurich, Switzerland) · 2024Article
- Open access repository-scale propagated nearest neighbor suspect spectral library for untargeted metabolomics.Nature communications · 2023Article
- An Automated Centrifugal Microfluidic Platform for Efficient Multistep Blood Sample Preparation and Clean-Up towards Small Ion-Molecule Analysis.Micromachines · 2023Article
- The inhibition of ORMDL3 prevents Alzheimer's disease through ferroptosis by PERK/ATF4/HSPA5 pathway.IET nanobiotechnology · 2023Article
- Discovering Hair Biomarkers of Alzheimer's Disease Using High Resolution Mass Spectrometry-Based Untargeted Metabolomics.Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlzheimer's disease (AD) is associated with altered metabolites. This study aimed to determine the validity of using circulating metabolites to differentiate AD from other dementias.
methodsBlood metabolites were measured in three data sets. Data set 1 (controls, 27; AD, 28) was used for analyzing differential metabolites. Data set 2 (controls, 93; AD, 92) was used to establish a diagnostic AD model with use of a metabolite panel. The model was applied to Data set 3 (controls, 76; AD, 76; other dementias, 205) to verify its capacity for differentiating AD from other dementias.
resultsData set 1 revealed 7 upregulated and 77 downregulated metabolites. In Data set 2, a panel of 11 metabolites was included in a model that could distinguish AD from controls. In Data set 3, this panel was used to successfully differentiate AD from other dementias. DISCUSSION: This study revealed an AD-specific panel of 11 metabolites that may be used for AD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.